The recently approved type 1 FLT3 inhibitors have led to improved survival of FLT3-ITD+ AML patients over standard chemotherapy, however, initial responses are often variable and long-term benefits with either monotherapy or combination therapy are rarely achieved5–8. Here, FLT3 is linked to acute myeloid leukemia.